Not losing weight on WEGOVY?
Before week 17 you haven’t reached a maintenance dose: WEGOVY starts at 0.25 mg and steps up every four weeks. In the label’s largest trial, weight kept coming off for months after that, though about one in six on 2.4 mg hadn’t lost 5% by week 68.1
On this page
Weeks 1 to 16: the dose is still climbing
WEGOVY isn’t started at the dose it’s meant to be kept on. The label sets out four steps of four weeks each, and it names the first four doses for what they are: a starting dose and three escalation doses. Maintenance starts at week 17.1
| Weeks | Weekly dose | The label calls it |
|---|---|---|
| 1 to 4 | 0.25 mg | Starting dosage |
| 5 to 8 | 0.5 mg | Escalation |
| 9 to 12 | 1 mg | Escalation |
| 13 to 16 | 1.7 mg | Escalation |
| 17 onward | 1.7 or 2.4 mg | Maintenance |
WEGOVY prescribing information, Table 1 and section 2.2 (label revised 6/2026). The maintenance row is the label’s dosage for weight reduction in adults, and of the two it recommends 2.4 mg.
The label gives one reason for starting low, and it isn’t weight:
Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)].
So a slow start is built in. At week 6 you’re on about a fifth of the recommended maintenance dose. Judging it by the scale then is judging it before it has reached the dose the trials were built around.
The label’s trigger for holding a step is a dose that isn’t tolerated. How long semaglutide side effects last covers when those side effects peak across these same weeks.
Week 20: what the trial measured
One of the label’s trials, Study 5, weighed everyone at week 20, which gives a direct look at the escalation months. All 902 people took WEGOVY for a 20-week run-in that included the 16 weeks of escalation. 99 of them stopped before week 20, most often because of side effects. The 803 who reached 2.4 mg averaged 107.2 kg at the start and 96.1 kg at week 20.1
That’s about 11 kg, roughly a tenth of their starting weight, in the first five months. The label adds its own warning about reading too much into it:
Because patients who discontinued WEGOVY injection during titration and those who did not reach the 2.4 mg weekly dose were not eligible for the randomized-treatment period, the results may not reflect the experience of patients in the general population who are first starting WEGOVY injection.
The label’s time-course charts for its trials tell the same story in pictures. The WEGOVY lines fall steeply through the escalation weeks and keep falling long after week 16.
Weeks 17 to 68: slower, then flat
Study 2 is the label’s largest weight trial: 1,961 adults with obesity, or with overweight and a weight-related condition, and no diabetes. After 68 weeks, average weight had fallen 14.9% on WEGOVY 2.4 mg and 2.4% on placebo. In the label’s chart for that trial, the WEGOVY line flattens over the final months instead of falling to the end.1
| Lost at least | WEGOVY 2.4 mg | Placebo |
|---|---|---|
| 5% | 83.5% | 31.1% |
| 10% | 66.1% | 12% |
| 15% | 47.9% | 4.8% |
| 20% | 30.2% | 1.7% |
WEGOVY prescribing information, section 14.2, Table 8 (label revised 6/2026). 1,306 people on WEGOVY 2.4 mg and 655 on placebo; missing week-68 weights were imputed, as the table notes.
Read the first row the other way round and it answers the question you came with. About one person in six on WEGOVY in Study 2 had not lost 5% of their starting weight by week 68. Slow or stalled weight loss happened in the trial too, among people assigned to 2.4 mg, over more than a year.
Who lost less in the trials
People with type 2 diabetes lost less. Study 3 enrolled 807 adults with type 2 diabetes, and average weight fell 9.6% on WEGOVY 2.4 mg against 3.4% on placebo. 67.4% of them lost at least 5%, so about a third didn’t. It’s a separate trial with a different population, not a head-to-head, but it’s the number that applies if you have diabetes.1
The maintenance dose matters too. Study 6 put 401 East Asian adults on 1.7 mg, 2.4 mg or placebo for 68 weeks. Weight fell 9.6% on 1.7 mg, 13.2% on 2.4 mg and 2.1% on placebo. If your prescriber settled on 1.7 mg, that’s the comparison the label has for you.1
None of these trials tested the drug on its own: the label describes every one of them as WEGOVY “in conjunction with a reduced-calorie diet and increased physical activity”. In six of them, everyone was told to eat about 500 fewer calories a day and to get at least 150 minutes of activity a week, starting with the first dose. The label makes the pairing part of the instructions:1
Administer WEGOVY in combination with a reduced-calorie diet and increased physical activity.
The label doesn’t name a group it didn’t work for. Its words on that are plain: “A reduction in body weight was observed with WEGOVY irrespective of age, sex, race, ethnicity, BMI at baseline, body weight (kg) at baseline, and level of renal function impairment.”
After week 17: what the label says about the dose
Maintenance isn’t one fixed number. For weight reduction in adults the label names two maintenance doses, tells the prescriber what to weigh, and allows one more step for some people:
The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.
Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1),Clinical Studies (14.2)].
For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.
On the standard schedule, 2.4 mg starts at week 17, so week 21 is the earliest that last step can come up. In Study 8, which followed 1,407 adults with obesity and no diabetes for 72 weeks, weight fell 18.8% on 7.2 mg, 15.5% on 2.4 mg and 3.9% on placebo.1
That’s the closest the label comes to a checkpoint. It doesn’t name a week by which you should have lost a set amount; it leaves the maintenance dose to “treatment response and tolerability”, which is a judgment your prescriber makes with your numbers in front of them.
A different maintenance dose can also mean a different price. What it costs as the weeks go on shows whether a seller’s price moves when the dose does, and what semaglutide costs by dose lists the figures sellers publish for each step.
If you stop, or miss weeks
Study 5 also shows what happens when the drug stops. At week 20, the 803 people were split: some stayed on WEGOVY and the rest were switched to placebo without knowing it. By week 68, the group that stayed on had lost a further 7.9% of their week-20 weight, and the placebo group had regained 6.9%.1 The weight-regain evidence considers stopping treatment separately from a slow response while taking it.
A gap has its own rule. After two or more missed doses in a row, the WEGOVY label restarts the escalation at a lower dose, which sets the clock back again. If you missed a semaglutide dose quotes that instruction in full.
Questions
How long does it take to start losing weight on WEGOVY?
The label doesn’t give a start date. In its Study 5, the 803 people who reached 2.4 mg averaged 107.2 kg at the start and 96.1 kg at week 20, and the label’s time-course charts show weight falling from the first weeks of escalation.
Should I ask for a higher dose?
That’s your prescriber’s call, and the label gives them the rules: 1.7 mg or 2.4 mg for maintenance, chosen on treatment response and tolerability, and 7.2 mg only after at least 4 weeks on 2.4 mg when more weight reduction is clinically indicated.
Does OZEMPIC work on the same timeline?
OZEMPIC has its own label, for adults with type 2 diabetes, and its dose goes up to 2 mg based on blood sugar control rather than weight, so WEGOVY’s trial weeks don’t carry over to it.2
What if I’m on compounded semaglutide?
The trials and the dose rules here belong to WEGOVY. A compounded preparation isn’t WEGOVY and has no approved label to compare it with, so the schedule that governs it is the one your prescriber and pharmacy gave you.
The same five steps, and how OZEMPIC’s differ from them, are on the semaglutide dosage chart.
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.